In patients with homozygous familial hypercholesterolemia (HoFH), treatment with the PCSK9 inhibitor alirocumab was found to significantly reduce low-density lipoprotein cholesterol (LDL-C) levels, as well as other atherogenic lipids and lipoproteins, according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.